阿帕替尼治疗晚期胃癌的临床疗效及预后

发布时间：2018-03-26 13:17

本文选题：阿帕替尼　切入点：晚期胃癌　出处：《世界华人消化杂志》2016年05期

【摘要】：目的:探讨阿帕替尼用于二线及二线以上治疗失败的晚期胃癌患者的临床疗效分析及预后因素研究.方法:研究对象为2014-10/2015-08曾接受过二线及二线以上治疗失败的60例晚期胃癌患者,均经病理确诊.给予阿帕替尼口服850m g/d,直至疾病进展,观察临床疗效及不良反应发生情况.应用Kaplan-Meier法进行生存分析.结果:根据实体瘤的疗效评定标准(Response Evaluation Criteria in Solid Tumors,RECIST)全部可评价疗效.其中完全缓解(complete response,CR)占0%(0/60),部分缓解(partial response,PR)占3.33%(2/60),疾病稳定(stable disease,SD)占38.33%(23/60),疾病进展(progressive disease,PD)占58.33%(35/60).客观缓解率(CR+PR)为3.33%,疾病控制率(CR+PR+SD)为38.33%(23/60).中位无进展生存期为3.76 mo.甲胎蛋白(a-f e t o p r o t e i n,A F P)阳性胃癌患者的疾病控制以及生存受益优于AFP阴性患者.高血压、骨髓抑制是影响阿帕替尼治疗的最主要的不良反应.结论:阿帕替尼治疗二线及二线以上治疗失败的晚期胃癌仍有较好的疾病控制及生存获益,不良反应可控制,值得临床上广泛应用.
[Abstract]:Objective: to investigate the clinical efficacy and prognostic factors of apatinib in patients with advanced gastric cancer who failed in the treatment of second line or above. Methods: 60 patients who failed in treatment of second line or more than second line in 2014-10 / 2015-08 were studied. Patients with advanced gastric cancer, Apatinib was given 850mg / d orally until the disease progressed. Clinical efficacy and adverse reactions were observed. Survival analysis was carried out by Kaplan-Meier method. Results: response Evaluation Criteria in Solid tumors were all evaluated according to the evaluation standard of the curative effect of solid tumors, in which complete response response (CR) accounted for 0% / 0 60%, and partial remission was found in 0% / 0 60% of patients with solid tumors. Partial response PRA (3.33 / 60), stable disease SDR (38.33 / 60), progressive disease PDD (58.3335 / 60), objective remission rate (CR PRR) = 3.33 and CR PR (SDR) = 38.33 / 2360%. The progression-free survival period was 3.76 moths. The disease control and survival benefits of cancer patients are better than those of AFP negative patients. Bone marrow depression is the most important adverse reaction affecting apatinib treatment. Conclusion: Apatinib still has better disease control and survival benefits in patients with advanced gastric cancer who failed in the treatment of second line or more than the second line, and the adverse reactions can be controlled. It is worthy of extensive clinical application.
【作者单位】：郑州大学第一附属医院肿瘤内科;
【分类号】：R735.2

【相似文献】